Non-Alcoholic Fatty Liver Disease and Its Association with Cardiovascular Risk Factors: A Cross-Sectional Study
DOI:
https://doi.org/10.55489/ijmr.1401202692Keywords:
Cardiovascular diseases, Diabetes Mellitus, dyslipidemia, hypertension, metabolic syndromeAbstract
Introduction: Non-alcoholic fatty liver disease is the most common chronic liver disease worldwide, closely associated with obesity, type 2 diabetes mellitus and metabolic syndrome. Beyond hepatic complications, NAFLD is increasingly recognized as a multisystem disorder with cardiovascular disease being the leading cause of mortality. The present study aimed to evaluate the prevalence of NAFLD and its correlation with cardiovascular risk factors.
Methods: A retrospective cross-sectional analysis was conducted in Stoke-on-Trent, UK on 183 adult patients diagnosed with NAFLD by ultrasonography. Patients with significant alcohol intake, viral hepatitis, autoimmune or metabolic liver disease were excluded. Demographic, clinical, and biochemical data including cardiovascular risk factors were analyzed. Statistical tests included Chi-square, t-test/ANOVA, and binory logistic regression, with p <0.05 considered significant.
Results: The mean age of participants was 44.8 ± 11.2 years, with a male predominance (64.5%). The most prevalent cardiovascular risk factors were obesity (74.9%) and dyslipidemia (66.1%), followed by hypertension (50.3%), diabetes mellitus (42.6%), and smoking (26.8%). Higher NAFLD grades were significantly associated with increased prevalence of hypertension, diabetes, and dyslipidemia. Biochemical parameters including fasting blood sugar, cholesterol, and triglycerides worsened with disease severity, while HDL levels declined (all p <0.05). Obesity, diabetes, and hypertension as independent predictors of advanced NAFLD.
Conclusion: NAFLD is associated with obesity, diabetes, and hypertension, which also predict disease severity. These findings highlight the need for early screening, comprehensive risk assessment, and integrated management strategies to address both hepatic and cardiovascular outcomes in NAFLD patients.
References
1. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024 Sep;81(3):492-542. DOI: https://doi.org/10.1016/j.jhep.2024.04.031 PMid:38851997
2. Barbhuiya PA, Ahmed A, Pathak MP. Advancing metabolic dysfunction associated steatotic liver disease (MASLD) Treatment: Exploring novel formulations and therapies. J Drug Deliv Sci Technol 2026;115:107702. DOI: https://doi.org/10.1016/j.jddst.2025.107702
3. Mao Y, Du J, Li B, Wang J, Xuan S, Yang S, Tang Z, Wang M. Global burden of NAFLD 1990-2021 and projections to 2035: Results from the Global Burden of Disease study 2021. PLoS One. 2025 Aug 22;20(8):e0330504. DOI: https://doi.org/10.1371/journal.pone.0330504 PMid:40845036 PMCid:PMC12373163
4. Rinella ME, Sookoian S. From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease. J Lipid Res. 2024 Jan;65(1):100485. DOI: https://doi.org/10.1016/j.jlr.2023.100485 PMid:38103785 PMCid:PMC10824973
5. Hernandez-Vila E. A review of the JNC 8 Blood Pressure Guideline. Tex Heart Inst J. 2015 Jun 1;42(3):226-8. DOI: https://doi.org/10.14503/THIJ-15-5067 PMid:26175633 PMCid:PMC4473614
6. UpToDate, Inc. American Diabetes Association criteria for the diagnosis of diabetes. In: UpToDate [Internet]. Waltham (MA): UpToDate Inc.; [cited 2024 June 6]. Available from: https://www.uptodate.com/contents/image?imageKey=ENDO/61853.
7. Amsterdam EA, Wenger NK, Brindis RG, Casey DE, Ganiats TG, Holmes DR, et al. 2014 AHA/ACC guideline for the management of patients with non-st-elevation acute coronary syndromes: A report of the American college of cardiology/American heart association task force on practice guidelines. Circulation 2014;130:e344-426. DOI: https://doi.org/10.1161/CIR.0000000000000134
8. Koh JC, Loo WM, Goh KL, Sugano K, Chan WK, Chiu WYP, et al. Asian consensus on the relationship between obesity and gastrointestinal and liver diseases. Journal of Gastroenterology and Hepatology (Australia) 2016;31:1405-13. DOI: https://doi.org/10.1111/jgh.13385 PMid:27010240
9. Shil BC, Saha M, Ahmed F, Dhar SC. Nonalcoholic Fatty Liver Disease: Study of Demographic and Predictive Factors. Euroasian J Hepatogastroenterol 2015;5(1):4-6. DOI: https://doi.org/10.5005/jp-journals-10018-1119 PMid:29201676 PMCid:PMC5578510
10. Lin Y, Feng X, Cao X, Miao R, Sun Y, Li R, et al. Age patterns of nonalcoholic fatty liver disease incidence: heterogeneous associations with metabolic changes. Diabetol Metab Syndr 2022;14(1):181. DOI: https://doi.org/10.1186/s13098-022-00930-w PMid:36443867 PMCid:PMC9706887
11. Liu C, Liu T, Zhang Q, Jia P, Song M, Zhang Q, et al. New-Onset Age of Nonalcoholic Fatty Liver Disease and Cancer Risk. JAMA Netw Open 2023;6(9):e2335511. DOI: https://doi.org/10.1001/jamanetworkopen.2023.35511 PMid:37747732 PMCid:PMC10520743
12. Nagral A, Bangar M, Menezes S, Bhatia S, Butt N, Ghosh J, et al. Gender Differences in Nonalcoholic Fatty Liver Disease. Euroasian J Hepatogastroenterol. 2022 Jul;12(Suppl 1):S19-S25. DOI: https://doi.org/10.5005/jp-journals-10018-1370 PMid:36466099 PMCid:PMC9681575
13. G Subashini, T Murugaraj, Elayaperumal S, Firthous.M J, Thilagam.S R. The Impact Of Bmi And Gender Disparities On Nafld Among Young Adults. Journal of Neonatal Surgery 2025;14(6):49-55. DOI: https://doi.org/10.52783/jns.v14.2828
14. Lonardo A, Nascimbeni F, Ballestri S, Fairweather D, Win S, Than TA, et al. Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps. Hepatology. 2019 Oct;70(4):1457-1469. DOI: https://doi.org/10.1002/hep.30626 PMid:30924946 PMCid:PMC6766425
15. Bhaumik R, Bhat DrSA, Bhaumik DrP. Association Between Non-Alcoholic Fatty Liver Disease, Serum Aminotransferases And Body Mass Index: A Cross-Sectional Study. African Journal of Biomedical Research 2024;27:763-8. DOI: https://doi.org/10.53555/AJBR.v27i4S.3679
16. Abangah G, Yousef A, Asadollahi R, Veisani Y, Rahimifar P, Alizadeh S. Correlation of Body Mass Index and Serum Parameters With Ultrasonographic Grade of Fatty Change in Non-alcoholic Fatty Liver Disease. Iran Red Crescent Med J 2014;16(1):e12669. DOI: https://doi.org/10.5812/ircmj.12669 PMid:24719704 PMCid:PMC3964422
17. Ma C, Yan K, Wang Z, Zhang Q, Gao L, Xu T, et al. The association between hypertension and nonalcoholic fatty liver disease (NAFLD): literature evidence and systems biology analysis. Bioengineered 2021;12(1):2187-2202. DOI: https://doi.org/10.1080/21655979.2021.1933302 PMid:34096467 PMCid:PMC8806441
18. Ng CH, Wong ZY, Chew NWS, Chan KE, Xiao J, Sayed N, et al. Hypertension is prevalent in non-alcoholic fatty liver disease and increases all-cause and cardiovascular mortality. Front Cardiovasc Med. 2022;9:942753. DOI: https://doi.org/10.3389/fcvm.2022.942753 PMid:36003916 PMCid:PMC9393330
19. En Li Cho E, Ang CZ, Quek J, Fu CE, Lim LKE, Heng ZEQ, et al. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis. Gut. 2023 Nov;72(11):2138-2148. DOI: https://doi.org/10.1136/gutjnl-2023-330110 PMid:37491159
20. Kumar P, Rawat S, Kakar A, Sinha AK. Prevalence of non-alcoholic fatty liver disease among diabetes, prediabetes and healthy population. J Family Med Prim Care. 2022 Dec;11(12):7640-7643. DOI: https://doi.org/10.4103/jfmpc.jfmpc_856_22 PMid:36994063 PMCid:PMC10041021
21. Chalasani, Naga, Zobair Younossi, Joel E. Lavine, Michael Charlton, Kenneth Cusi, Mary Rinella, Stephen A. Harrison, Elizabeth M. Brunt, and Arun J. Sanyal. 2018. "The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance from the American Association for the Study of Liver Diseases." Hepatology 67(1):328-57. DOI: https://doi.org/10.1002/hep.29367 PMid:28714183
22. Martin A, Lang S, Goeser T, Demir M, Steffen HM, Kasper P. Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease. Curr Atheroscler Rep 2022;24(7):533-546. DOI: https://doi.org/10.1007/s11883-022-01028-4 PMid:35507279 PMCid:PMC9236990
23. Teng ML, Ng CH, Huang DQ, Chan KE, Tan DJ, Lim WH, Yang JD, Tan E, Muthiah MD. Global incidence and prevalence of nonalcoholic fatty liver disease. Clin Mol Hepatol. 2023 Feb;29(Suppl):S32-S42. DOI: https://doi.org/10.3350/cmh.2022.0365 PMid:36517002 PMCid:PMC10029957
24. Karjoo S, Auriemma A, Fraker T, Bays HE. Nonalcoholic fatty liver disease and obesity: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. Obesity Pillars 2022;3:100027. DOI: https://doi.org/10.1016/j.obpill.2022.100027 PMid:37990727 PMCid:PMC10661876
25. Jang HR, Kang D, Sinn DH, Gu S, Cho SJ, Lee JE, et al. Nonalcoholic fatty liver disease accelerates kidney function decline in patients with chronic kidney disease: a cohort study. Sci Rep. 2018 Mar 16;8(1):4718. DOI: https://doi.org/10.1038/s41598-018-23014-0. Erratum in: Sci Rep. 2021 May 21;11(1):11139. DOI: https://doi.org/10.1038/s41598-021-90150-5. PMID: 29549269; PMCID: PMC5856790.
26. Li G, Peng Y, Chen Z, Li H, Liu D, Ye X. Bidirectional Association between Hypertension and NAFLD: A Systematic Review and Meta-Analysis of Observational Studies. Int J Endocrinol 2022;2022:8463640. DOI: https://doi.org/10.1155/2022/8463640 PMid:35371259 PMCid:PMC8970889
27. Ryoo JH, Suh YJ, Shin HC, Cho YK, Choi JM, Park SK. Clinical association between non-alcoholic fatty liver disease and the development of hypertension. J Gastroenterol Hepatol. 2014 Nov;29(11):1926-1931. DOI: https://doi.org/10.1111/jgh.12643 PMid:24910023
28. Atan NAD, Koushki M, Motedayen M, Dousti M, Sayehmiri F, Vafaee R, et al. Type 2 diabetes mellitus and non-alcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterol Hepatol Bed Bench 2017 Winter;10(Suppl1):S1-S7. PMID: 29511464; PMCID: PMC5838173.
29. Chen X, Shi F, Xiao J, Huang F, Cheng F, Wang L, et al. Associations Between Abdominal Obesity Indices and Nonalcoholic Fatty Liver Disease: Chinese Visceral Adiposity Index. Front Endocrinol (Lausanne) 2022;13:831960. DOI: https://doi.org/10.3389/fendo.2022.831960 PMid:35360076 PMCid:PMC8960385
30. Chambergo-Michilot D, Rodrigo-Gallardo PK, Huaman MR, Vasquez-Chavesta AZ, Salinas-Sedo G, Toro-Huamanchumo CJ. Hypertension and Histopathology Severity of Non-Alcoholic Fatty Liver Disease Among Adults with Obesity: A Cross-Sectional Study. Clin Exp Gastroenterol 2023;16:129-136. DOI: https://doi.org/10.2147/CEG.S402498 PMid:37601009 PMCid:PMC10437097
31. Suryawanshi NV, Pai K, Radhakrishnan R, Sawardekar V, Bhaisare SD. Prevalence of Non-Alcoholic Fatty Liver Disease and Its Correlation with Coronary Risk Factors in Patients with Type 2 DM. International Journal of Medical Research & Health Sciences (ijmrhs). 2023;12(2):78-84.
32. Zhu Z, Yang N, Fu H, Yuan G, Chen Y, Du T, et al. Associations of lipid parameters with non-alcoholic fatty liver disease in type 2 diabetic patients according to obesity status and metabolic goal achievement. Front Endocrinol (Lausanne) 2022;13:1002099. DOI: https://doi.org/10.3389/fendo.2022.1002099 PMid:36187115 PMCid:PMC9523101
33. Zhang QQ, Lu LG. Nonalcoholic Fatty Liver Disease: Dyslipidemia, Risk for Cardiovascular Complications, and Treatment Strategy. J Clin Transl Hepatol 2015;3(1):78-84. DOI: https://doi.org/10.14218/JCTH.2014.00037 PMid:26357637 PMCid:PMC4542078
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Faraz Ahmed, Umme Aimen, Syed Mubashiruddin, Sumaiya Farshori
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
The authors retain the copyright of their article, with first publication rights granted to Medsci Publications.
